

Announcement Summary

Entity name

ANATARA LIFESCIENCES LTD

Date of this announcement

Monday December 13, 2021

The +securities the subject of this notification are:

♥ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	Options expiring 14 November 2025 exercisable at \$0.225 ea	1,800,000	09/12/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ANATARA LIFESCIENCES LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

Registration number

ABN

41145239872

1.3 ASX issuer code

ANR

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

13/12/2021



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

🗹 +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

New +securities issued under an +employee incentive scheme

ASX +security code	+Security description
New class - code to be confirmed	Options expiring 14 November 2025 exercisable at \$0.225 ea
+Security type	ISIN code

Date the +securities the subject of this notification were issued

9/12/2021

Options

Will all the +securities issued in this class rank equally in all respects from their issue date?

✓ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?
⊗ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
David Brookes - Director	David Brookes	900,000
Sue MacLeman - Director	Dalroar Pty Ltd as t'ee for MacLeman Investment Trust	450,000
Jane Ryan - Director	Jane Ryan	450,000

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?


✓ Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued

Approved by Shareholders at the Annual General Meeting held on 16 November 2021. https://anataralifesciences.com/investors/corporate-governance/

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.22500000	14/11/2025





Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

Description

Options exercisable at \$0.225 ea and expire 14 November 2025

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

https://anataralifesciences.com/investors/corporate-governance/

Any other information the entity wishes to provide about the +securities the subject of this notification

- a. David Brookes: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023; expire 14 November 2025
- b. Dalroar Pty Ltd as t'ee for MacLeman Investment Trust (Sue MacLeman): 450,000 at \$0.225 ea; vesting 225,000 16 November 2022 & 225,000 16 November 2023; expire 14 November 2025
- c. Jane Ryan: 450,000 at \$0.225 ea; vesting 225,000 16 November 2022 & 225,000 16 November 2023; expire 14 November 2025

Issue details

Number of +securities

1,800,000



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

	Total number of
ASX +security code and description	+securities on issue

ANR: ORDINARY FULLY PAID 71,316,997

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
ANRAI : OPTION EXPIRING 17-FEB-2024 EX 73.6C	600,000
ANRAL : OPTION EXPIRING 03-DEC-2023 EX \$0.25	1,500,000
ANRAM : OPTION EXPIRING 03-DEC-2022 EX \$0.2476	617,704
ANRAK : PERFORMANCE RIGHTS	38,624
ANRAN : OPTION EXPIRING 18-AUG-2025 EX \$0.2256	260,000
New class - code to be confirmed : Options expiring 14 November 2025 exercisable at \$0.225 ea	1,800,000



Part 5 - Other Listing Rule requirements

- 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?
 ☑ Yes
- 5.1a Select the number of the applicable exception in Listing Rule 7.2

13